Schizophrenia proteomics: Biomarkers on the path to laboratory medicine?

Diagnostic Pathology

Volumn 1, Issue 1, 2006, Pages

  Lakhan, Shaheen Emmanuel ^a  

^a Global Neuroscience Initiative Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248190080     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-1-11     Document Type: Article

References (95)

1. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3(4):355-366.
2. Sunderland T, Gur RE, Arnold SE: The use of biomarkers in the elderly: current and future challenges. Biol Psychiatry 2005, 58(4):272-276.
3. Riley B, Kendler KS: Molecular genetic studies of schizophrenia. EurJ Hum Genet 2006, 14(6):669-680.
4. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoega T, Helgason T: Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003, 73(1):34-48.
5. Homfray T, Holland T, Patton M: A new X-linked mental retardation syndrome. Clin Dysmorphol 1995, 4(4):289-293.
6. Berrettini WH: Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry 2000, 48(6):531-538.
7. Stopkova P, Saito T, Fann CS, Papolos DF, Vevera J, Paclt I, Zukov I, Stryjer R, Strous RD, Lachman HM: Polymorphism screening of PIP5K2A: a candidate gene for chromosome I Op-linked psychiatric disorders. Am J Med Genet B Neurofisychiatr Genet 2003, 123(1):50-58.
8. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T: Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004, 9(4):406-416.
9. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S: Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362(9386): 798-805.
10. Eastwood SL, Harrison PJ: Decreased expression of vesicular glutamate transporter I and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 2005, 73(2-3): 159-172.
11. Akbarian S, Ruehl MG, Bliven E, Luiz LA, Peranelli AC, Baker SP, Roberts RC, Bunney WEJ, Conley RC, Jones EG, Tamminga CA, Guo Y: Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2005, 62(8):829-840.
12. Mclnnes LA, Lauriat TL: RNA metabolism and dysmyelination in schizophrenia. Neurosci Biobehav Rev 2006, 30(4):551 -561.
13. Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19(3): 1720-1730.
14. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, EngJK, Bumgarner R, Goodlett DR, Aebersold R, Hood L: Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001, 292(5518):929-934.
15. Hamacher M, Meyer HE: HUPO Brain Proteome Project: aims and needs in proteomics. Expert Rev Proteomics 2005, 2(1): 1-3.
16. Edgar PF, Schonberger SJ, Dean B, Faull RL, Kydd R, Cooper GJ: A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol Psychiatry 1999, 4(2): 173-178.
17. Niu N, Rice SR, Heston LL, Sobell JL: Multiple missense muttions in the diazepam binding inhibitor (DBI) gene identified in schizophrenia but lack of disease association. Am J Med Genet B Neuropsychiatr Genet 2004, 125 (1): 10-19.
18. Ohnuma T, Suzuki T, Arai H: Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Prog Neuropsychophormacol Biol Psychiatry 2005, 29(6):889-894.
19. Edgar PF, Douglas JE, Cooper GJ, Dean B, Kydd R, Faull RL: Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia. Mol Psychiatry 2000, 5(1):85-90.
20. Kahl R, Kampkotter A, Watjen W, Chovolou Y: Antioxidant enzymes and apoptosis. Drug Metab Rev 2004, 36(3-4):747-762.
21. Fukata Y, Kimura T, Kaibuchi K: Axon specification in hippocampal neurons. Neurosci Res 2002, 43(4):305-315.
22. Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H, Kaibuchi K: CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat Cell Biol 2003, 5(9):819-826.
23. Kubota H, Hynes G, Willison K: The chaperonin containing t-complex polypeptide 1 (TCP-1). Multisubunit machinery assisting in protein folding and assembly in the eukaryotic cytosol. Eur J Biochem 1995, 230(1):3-16.
24. Erdo F, Trapp T, Mies G, Hossmann KA: Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in mice. Acta neuropathologica 2004, 107(2): 127-136.
25. Yoo BC, Fountoulakis M, Dierssen M, Lubec G: Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein I. J Neural Transm Suppl 2001:321-334.
26. Chauhan V, Chauhan A: Oxidative stress in Alzheimer's disease. Pathophysiology 2006.
27. Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G: Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2000, 2(2-3):293-310.
28. Suzuki Y, Tanaka M, Sohmiya M, Ichinose S, Omori A, Okamoto K: Identification of nitrated proteins in the normal rat brain using a proteomics approach. Neurol Res 2005, 27(6):630-633.
29. Levi A, Kohn Y, Kanyas K, Amann D, Pae CD, Hamdan A, Segman RH, Avidan N, Karni O, Korner M, Jun TY, Beckmann JS, Macciardi F, Lerer B: Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: increased evidence for linkage and reduced linkage interval. Eur J Hum Genet 2005, 13(6):763-771.
30. Jiang L, Lindpaintner K, Li HF, Gu NF, Langen H, He L, Fountoulakis M: Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 2003, 25(1):49-57.
31. Qin X, Tso P: The role of apolipoprotein AIV on the control of food intake. Curr Drug Targets 2005, 6(2): 145-151.
32. Liu M, Doi T, Shen L, Woods SC, Seeley RJ, Zheng S, Jackman A, Tso P: Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. American journal of physiology 2001, 280(5):R 1382-7.
33. Krebs M, Leopold K, Hinzpeter A, Schaefer M: Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother 2006, 7(8): 1005-1016.
34. Guerreiro N, Gomez-Mancilla B, Charmont S: Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid. Proteorne Sci 2006, 4:7.
35. Mei J, Kolbin D, Kao HT, Porton B: Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 2006, 84(2-3):204-213.
36. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C: Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004, 11(10):907-914.
37. Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman CN, Whiteley G, Liotta L, Camphausen K: Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 2006, 66(3): 1844-1850.
38. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF: Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004, 172(4 Pt 1): 1302-1305.
39. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003, 95 (9):661-668.
40. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF: Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006, 7(3):230-240.
41. Bienvenut WV, Deon C, Pasquarello C, Campbell JM, Sanchez JC, Vestal ML, Hochstrasser DF: Matrix-assisted laser desorption/ionization-tandem mass spectrometry with high resolution and sensitivity for identification and characterization of proteins. Proteomics 2002, 2(7):868-876.
42. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20(18):3551-3567.
43. Ethier M, Figeys D, Perreault H: N-glycosylation analysis using the StrOligo algorithm. Methods Mol Biol 2006, 328:187-197.
44. Medzihradszky KF: Peptide sequence analysis. Methods Enzymol 2005, 402:209-244.
45. Wang D, Kalume D, Pickart C, Pandey A, Cotter RJ: Identification of Protein Ubiquitylation by Electrospray Ionization Tandem Mass Spectrometric Analysis of Sulfonated Tryptic Peptides. Anal Chem 2006, 78(11):3681-3687.
46. Omaetxebarria MJ, Hagglund P, Elortza F, Hooper NM, Arizmendi JM, Jensen ON: Isolation and Characterization of Glycosylphos-phatidylinositol-Anchored Peptides by Hydrophilic Interaction Chromatography and MALDI Tandem Mass Spectrometry. Anal Chem 2006, 78(10):3335-3341.
47. Elortza F, Nuhse TS, Foster LJ, Stensballe A, Peck SC, Jensen ON: Proteomic analysis of glycosylphosphatidylinositol-anchored membrane proteins. Mol Cell Proteomics 2003, 2(12): 1261-1270.
48. Sinibaldi L, De Luca A, Bellacchio E, Conti E, Pasini A, Paloscia C, Spalletta G, Caltagirone C, Pizzuti A, Dallapiccola B: Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat 2004, 24(6):534-535.
49. Vawter MP, Cannon-Spoor HE, Hemperly JJ, Hyde TM, VanderPutten DM, Kleinman JE, Freed WJ: Abnormal expression of cell recognition molecules in schizophrenia. Exp Neurol 1998, 149(2):424-432.
50. Eastwood SL, Harrison PJ: Cellular basis of reduced cortical reelin expression in schizophrenia. Am J Psychiatry 2006, 163(3):540-542.
51. Vawter MP, Howard AL, Hyde TM, Kleinman JE, Freed WJ: Alterations of hippocampal secreted N-CAM in bipolar disorder and synaptophysin in schizophrenia. Mol Psychiatry 1999, 4(5):467-475.
52. Shin YK, Lee HJ, Lee JS, Paik YK: Proteomic analysis of mammalian basic proteins by liquid-based two-dimensional column chromatography. Proteomics 2006, 6(4): 1143-1150.
53. Espina V, Milia J, Wu G, Cowherd S, Liotta LA: Laser capture microdissection. Methods Mol Biol 2006, 319:213-229.
54. Englert CR, Baibakov GV, Emmert-Buck MR: Layered expression scanning: rapid molecular profiling of tumor samples. Cancer Res 2000, 60(6): 1526-1530.
55. Hirsch SR, Weinberger D: Schizophrenia. 2nd edition. Malden, MA, Blackwell Science; 2003.
56. Cardno AG, Gottesman II: Twin studies of schizophrenia: from bow-and-arrow concordances to star wars MX and functional genomics. Am J Med Genet 2000, 97(1): 12-17.
57. Nuechterlein KH, Dawson ME, Ventura J, Gitlin M, Subotnik KL, Snyder KS, Mintz J, Bartzokis G: The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand Suppl 1994, 382:58-64.
58. O'Connor FW: A vulnerability-stress framework for evaluating clinical interventions in schizophrenia. Image J Nurs Sch 1994, 26(3):23 1-237.
59. Yank GR, Bentley KJ, Hargrove DS: The vulnerability-stress model of schizophrenia: advances in psychosocial treatment. Am J Orthopsychiatry 1993, 63(1):55-69.
60. Randrup A: Role of brain dopamine in the antipsychotic effect of neuroleptics. Evidence from studies of amphetamine-neuroleptic interaction. Mod Probl Pharmacopsychiatry 1970, 5:60-65.
61. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF: Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002, 5(3):267-271.
62. Perlstein WM, Dixit N K, Carter CS, Noll DC, Cohen JD: Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry 2003, 53(1):25-38.
63. Seamans JK, Yang CR: The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004, 74(1): 1-58.
64. Weiner I: The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 2003, 169(3-4):257-297.
65. Ben-Shachar D, Laifenfeld D: Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 2004, 59:273-296.
66. O'Tuathaigh C M, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL: Susceptibility genes for schizophrenia: Characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 2006.
67. Maier W, Zobel A, Kuhn KU: Clinical impact of recently detected susceptibility genes for schizophrenia. Dialogues Clin Neurosci 2006, 8(1):79-84.
68. Isohanni M, Lauronen E, Moilanen K, Isohanni I, Kemppainen L, Koponen H, Miettunen J, Maki P, Rasanen S, Veijola J, Tienari P, Wahlberg KE, Murray GK: Predictors of schizophrenia: evidence from the Northern Finland 1966 Birth Cohort and other sources. Br j Psychiatry Suppl 2005, 48:s4-7.
69. Association AP: Diagnostic and Statistical Manual of Mental Disorders. 4th, text-revision edition. New York , American Psychiatric Publishing; 2000.
70. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EV, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroentero/2005, 19 Suppl A:5-36.
71. Song JH, Kim HJ, Lee CH, Kim SJ, Hwang SY, Kim TS: Identification of gene expression signatures for molecular classification in human leukemia cells. Int J Oncol 2006, 29(1):57-64.
72. Gottesman II. Gould TD: The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003, 160(4):636-645.
73. Berrettini WH: Genetic bases for endophenotypes in psychiatric disorders. Dialogues Clin Neurosci 2005, 7(2):95-101.
74. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT, Tooney PA: Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 2006, 82(2-3): 175-183.
75. Baldridge EB, Bessen HA: Phencyclidine. Emerg Med Clin North Am 1990, 8(3):541-550.
76. Hurd YL, Pristupa ZB, Herman MM, Niznik HB, Kleinman JE: The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience 1994, 63(2):357-362.
77. Goldberg SC, Schooler NR, Hogarty GE, Roper M: Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Arch Gen Psychiatry 1977, 34(2): 171-184.
78. Hogarty GE, Goldberg S, Schooler N: Proceedings: Drug and sociotherapy in the aftercare of schizophrenic patients. Psychopharmacol Bull 1974, 10(4):47.
79. Hogarty GE, Goldberg SC: Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Arch Gen Psychiatry 1973, 28(1):54-64.
80. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF: Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 1974, 31 (5):603-608.
81. Casey DE: Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004, 65 Suppl 9:25-28.
82. Miller DD: Review and management of clozapine side effects. J Clin Psychiatry 2000, 61 Suppl 8:14-7; discussion 18-9.
83. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163(4):600-610.
84. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163(4):611-622.
85. Chen J, Lipska BK, Weinberger DR: Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models. Biol Psychiatry 2006.
86. Hajos M: Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 2006.
87. DeGrazia D: Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophr Res 2001, 51(1):77-86.
88. Dunn LB, Roberts LW: Emerging findings in ethics of schizophrenia research. Curr Opin Psychiatry 2005, 18(2): 111-119.
89. Wilson ST, Stanley B: Ethical concerns in schizophrenia research: looking back and moving forward. Schizophr Bull 2006, 32(1):30-36.
90. O'Mathuna D P: Human dignity in the Nazi era: implications for contemporary bioethics. BMCMed Ethics 2006, 7(1):2.
91. Wertz D: Eugenics is alive and well: a survey of genetic professionals around the world. Sci Context 1998, 11 (3-4):493-510.
92. Lakhan SE: The Emergence of Modern Biotechnology in China. Issues in Informing Science and Information Technology 2006, 3:333-353.
93. Quick JJ: Genetic discrimination and the need for federal legislation. J Biolaw Bus 2005, 8(1):22-26.
94. Krumm J: Genetic discrimination. Why Congress must ban genetic testing in the workplace, J Leg Med 2002, 23(4):491-521.
95. Palmer KT, Poole J, Rawbone RG, Coggon D: Quantifying the advantages and disadvantages of pre-placement genetic screening. Occup Environ Med 2004, 61 (5):448-453.